These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12048281)

  • 1. Re: All-cause mortality in randomized trials of cancer screening.
    Weiss NS; Koepsell TD
    J Natl Cancer Inst; 2002 Jun; 94(11):864-5; author reply 865-6. PubMed ID: 12048281
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: All-cause mortality in randomized trials of cancer screening.
    Gail MH; Katki HA
    J Natl Cancer Inst; 2002 Jun; 94(11):862; author reply 865-6. PubMed ID: 12048278
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: All-cause mortality in randomized trials of cancer screening.
    Begg CB; Bach PB
    J Natl Cancer Inst; 2002 Jun; 94(11):863-4; author reply 865-6. PubMed ID: 12048279
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: All-cause mortality in randomized trials of cancer screening.
    Church TR; Ederer F; Mandel JS
    J Natl Cancer Inst; 2002 Jun; 94(11):861; author reply 865-6. PubMed ID: 12048277
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: All-cause mortality in randomized trials of cancer screening.
    Kopans DB; Halpern E
    J Natl Cancer Inst; 2002 Jun; 94(11):863; author reply 865-6. PubMed ID: 12048280
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: All-cause mortality in randomized trials of cancer screening.
    Parker C; Dearnaley D
    J Natl Cancer Inst; 2002 Jun; 94(11):861-2; author reply 865-6. PubMed ID: 12048276
    [No Abstract]   [Full Text] [Related]  

  • 7. All-cause mortality in randomized trials of cancer screening.
    Black WC; Haggstrom DA; Welch HG
    J Natl Cancer Inst; 2002 Feb; 94(3):167-73. PubMed ID: 11830606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening trials are even more difficult than we thought they were.
    Juffs HG; Tannock IF
    J Natl Cancer Inst; 2002 Feb; 94(3):156-7. PubMed ID: 11830599
    [No Abstract]   [Full Text] [Related]  

  • 9. Demanding evidence.
    Handler S
    Minn Med; 2004 Feb; 87(2):7. PubMed ID: 15005122
    [No Abstract]   [Full Text] [Related]  

  • 10. A data-analytic approach for estimating lead time and screening benefit based on survival curves in randomized cancer screening trials.
    Kafadar K; Prorok PC
    Stat Med; 1994 Mar 15-Apr 15; 13(5-7):569-86. PubMed ID: 8023036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should we expect all-cause mortality reductions in large screening studies?
    Dobbin KK; Ebell M
    Br J Gen Pract; 2018 Jun; 68(671):290-291. PubMed ID: 29853594
    [No Abstract]   [Full Text] [Related]  

  • 12. Epidemiologic approach for cancer screening. Problems in design and analysis of trials.
    Prorok PC
    Am J Pediatr Hematol Oncol; 1992 May; 14(2):117-28. PubMed ID: 1530116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of cancer screening trials/randomized trials for evaluation of cancer screening.
    Miller AB
    World J Surg; 2006 Jul; 30(7):1152-62. PubMed ID: 16794902
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer screening.
    Kramer BS; Brawley OW
    Hematol Oncol Clin North Am; 2000 Aug; 14(4):831-48. PubMed ID: 10949776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammography studies revisited.
    Emory TH
    Minn Med; 2004 Feb; 87(2):7. PubMed ID: 15005121
    [No Abstract]   [Full Text] [Related]  

  • 16. Does screening for disease save lives in asymptomatic adults? Systematic review of meta-analyses and randomized trials.
    Saquib N; Saquib J; Ioannidis JP
    Int J Epidemiol; 2015 Feb; 44(1):264-77. PubMed ID: 25596211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An efficient randomised trial design for multi-cancer screening blood tests: nested enhanced mortality outcomes of screening trial.
    Hackshaw A; Berg CD
    Lancet Oncol; 2021 Oct; 22(10):1360-1362. PubMed ID: 34592178
    [No Abstract]   [Full Text] [Related]  

  • 18. Does the source of death information affect cancer screening efficacy results? A study of the use of mortality review versus death certificates in four randomized trials.
    Doria-Rose VP; Marcus PM; Miller AB; Bergstralh EJ; Mandel JS; Tockman MS; Prorok PC
    Clin Trials; 2010 Feb; 7(1):69-77. PubMed ID: 20156958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the benefits and harms of screening for breast cancer.
    Gøtzsche PC
    Int J Epidemiol; 2004 Feb; 33(1):56-64; discussion 69-73. PubMed ID: 15075145
    [No Abstract]   [Full Text] [Related]  

  • 20. Screening in clinical trials.
    Weiss NS
    Lancet; 2002 Sep; 360(9337):952; author reply 952. PubMed ID: 12354501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.